NEW YORK (GenomeWeb) – A research team from the UK has determined that a rapid molecular Ebola assay from BioMérieux subsidiary BioFire Defense is sufficiently sensitive and specific to be an attractive option for relatively low-throughput laboratories testing for the disease.

However, the assay and accompanying platform may not yet be suitable in outbreak situations or in labs with relatively high testing throughput, the researchers suggested.